A Phase 2 interventional study of VAY736 and Placebo in Primary Sjogren Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 56 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.
Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2017, is one of 9 in phase 2, and was the 3rd registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 4
First in 2014; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 240 across the 14 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Sjogren's Syndrome by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters
This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group trial that was divided into 4 study periods.
Period 1: A screening period of 4 weeks to assess patient eligibility. Patients could be re-screened only once, and no study-related re-screening procedure could be performed prior to written re-consent by the patient.
Period 2: A blinded treatment period of 24 weeks. At baseline, eligible patients were randomized to one of three ianalumab dose arms (VAY736 5 mg, 50 mg or 300 mg s.c.) or a placebo arm (placebo s.c.). Blinded study drug was administered every four weeks (q4w) for a 24-week period.
Except for Japan, randomization was stratified by baseline ESSDAI score (\<10 or ≥10 based on weighted scores). Separate blocks of randomization numbers were generated for patients in Japan versus the other countries participating to ensure that Japanese patients were equally distributed across all treatment groups in the study.
The primary endpoint was assessed at the end of Period 2 (Week 24). Treatment assignment in Period 2 remained double-blinded until the end of Period 3.
Period 3: An extended blinded treatment period of 28 weeks. After Week 24 assessments, patients in the ianalumab 300 mg arm were re-randomized in a 1:1 ratio to either continue on ianalumab 300 mg s.c. q4w or switch to matching placebo up to Week 52. Patients who received placebo during Period 2 were switched to ianalumab 150 mg s.c q4w up to Week 52. Patients who received 5 mg and 50 mg s.c. in Period 2 proceeded directly to safety follow-up (Period 4). Treatment assignment in Period 3 remained double-blinded.
Period 4: A post-treatment safety follow-up period. Patients who prematurely discontinued the study treatment at any time point or completed the treatment as planned entered the safety follow-up period. The minimum required duration of follow-up in the study was 20 weeks from the last administration of the study treatment (mandatory follow-up). The maximum duration of the follow-up was 2 years from the last dose of the study treatment, and it was defined by the level of recovery of CD19+ B-cells: conditional follow up (with reduced visit frequency) until CD19+ B-cell levels return to at least 80% of baseline or 50 cells/µL, whichever occurred first. Patients who had not yet recovered their B-cell counts two years after last ianalumab dosing were discharged from the study and had undergone their End of Study (EoS) visit. Patients who were treated with another immunomodulatory or immunosuppressive treatment (e.g., azathioprine, cyclophosphamide, high dose glucocorticosteroids) after completion of the minimum 20-week safety follow-up period were excluded from further safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VAY736 low
Biological: VAY736
VAY736 medium
Biological: VAY736
VAY736 high
Biological: VAY736
Placebo control
Other: Placebo
VAY736
Also known as: Ianalumab
Placebo control
Least Squares Mean Change From Baseline in ESSDAI Score at Week 24
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.
Time frame: Baseline, Week 24
Least Squares Mean Change From Baseline in ESSDAI Score at Weeks 4, 8, 12, and 16
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Least Squares Mean Change From Baseline in ESSPRI Score at Week 24
The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.
Time frame: Baseline, Week 24
Least Squares Mean Change From Baseline in ESSPRI Score at Weeks 4, 8, 12 and 16
The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks
The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.
Time frame: Baseline, Week 24
Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score at Weeks 4, 8, 12 and 16
The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.
Time frame: Baseline, Weeks 4, 8, 12 and 16
Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) Over 24 Weeks
The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).
Time frame: Baseline, Week 24
Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) at Weeks 4, 8, 12 and 16
The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).
Time frame: Baseline, Weeks 4, 8, 12 and 16
Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks
Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.
Time frame: Baseline, 24 weeks
Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) at Weeks 4, 8, 12 and 16
Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.
Time frame: Baseline, Weeks 4, 8, 12 and 16
Patient's Global Assessment (PaGA) Score at Weeks 4, 8, 12, 16 and 24
The PaGA of disease activity was performed using a 100 mm Visual Analog Scale (VAS) ranging from 0 (no disease activity) to 100 (maximal disease activity), in response to the question "Considering all the ways Sjögren's syndrome affects you, please draw a line on the scale to indicate how well you are doing today". A negative change from baseline is a favourable outcome.
Time frame: Weeks 4, 8, 12, 16 and 24
Least Squares Mean Change From Baseline in Salivary Flow Rate at Week 24
Change from baseline in salivary flow rate (unstimulated and stimulated) at 24 weeks as compared to placebo. Unstimulated saliva is a mix of serous and mucous secretions coming primarily from the submandibular and minor salivary glands. The parotid gland produces the largest volume of stimulated saliva. Stimulated saliva accounts for 80-90% of daily salivary production.
Time frame: Baseline, 24 weeks
Percent Change From Baseline in Whole Blood CD19+ B-cell Counts.
B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.
Time frame: Baseline, Week 24, Week 28
Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts
B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.
Time frame: Up to two years from last dose patient received.
Peak Serum Concentration of VAY736
Pharmacokinetic Concentrations This outcome only applies to patients who received at least one dose of VAY739 (so not applicable to placebo)
Time frame: baseline to week 24, then week 28
190 Patients were enrolled from 56 centers in 19 countries.
| Milestone | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | VAY736 - 150 mg | VAY736 300 mg - Placebo | VAY736 300 mg - VAY736 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 49 | 47 | 47 | 47 | 0 | 0 | 0 |
| Completed | 47 | 42 | 43 | 46 | 0 | 0 | 0 |
| Not completed | 2 | 5 | 4 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of informed consent | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: New therapy for indication | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with treatment | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | VAY736 - 150 mg | VAY736 300 mg - Placebo | VAY736 300 mg - VAY736 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 47 | 22 | 21 |
| Completed | 0 | 0 | 0 | 0 | 42 | 22 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 5 | 0 | 4 |
| Withdrew: Patient/guardian decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 5 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | VAY736 - 150 mg | VAY736 300 mg - Placebo | VAY736 300 mg - VAY736 300 mg |
|---|---|---|---|---|---|---|---|
| Started | 2 | 47 | 47 | 4 | 46 | 22 | 20 |
| Completed | 2 | 41 | 43 | 1 | 42 | 20 | 20 |
| Not completed | 0 | 6 | 4 | 3 | 4 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: New therapy for indication | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal of informed consent | 0 | 3 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 3 | 1 | 2 | 2 | 0 |
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Least Squares Mean Change From Baseline in ESSDAI Score at Week 24 | -6.39 ± 0.808 | -5.64 ± 0.850 | -6.93 ± 0.836 | -8.30 ± 0.828 |
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Week 4 | -3.73 ± 0.626 | -2.28 ± 0.661 | -3.37 ± 0.638 | -4.53 ± 0.651 |
| Week 8 | -4.13 ± 0.704 | -4.65 ± 0.733 | -4.73 ± 0.720 | -6.38 ± 0.717 |
| Week 12 | -5.45 ± 0.721 | -4.89 ± 0.762 | -5.69 ± 0.739 | -6.64 ± 0.739 |
| Week 16 | -6.08 ± 0.818 | -5.67 ± 0.852 | -6.17 ± 0.835 | -6.99 ± 0.836 |
The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Least Squares Mean Change From Baseline in ESSPRI Score at Week 24 | -1.71 ± 0.288 | -1.39 ± 0.304 | -1.70 ± 0.301 | -1.77 ± 0.295 |
The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Week 4 | -0.54 ± 0.236 | -0.67 ± 0.247 | -0.80 ± 0.241 | -0.88 ± 0.242 |
| Week 8 | -0.94 ± 0.242 | -0.84 ± 0.255 | -1.06 ± 0.251 | -1.8 ± 0.248 |
| Week 12 | -1.42 ± 0.265 | -1.36 ± 0.279 | -1.44 ± 0.273 | -1.23 ± 0.270 |
| Week 16 | -1.77 ± 0.263 | -1.27 ± 0.275 | -1.55 ± 0.271 | -1.55 ± 0.270 |
The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks | 9.05 ± 1.404 | 7.12 ± 1.502 | 6.48 ± 1.518 | 9.36 ± 1.436 |
The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Week 4 | 3.78 ± 1.175 | 6.32 ± 1.239 | 3.12 ± 1.229 | 3.39 ± 1.203 |
| Week 8 | 5.49 ± 1.222 | 6.36 ± 1.297 | 3.93 ± 1.303 | 5.98 ± 1.250 |
| Week 12 | 6.25 ± 1.349 | 8.17 ± 1.429 | 5.73 ± 1.427 | 6.05 ± 1.374 |
| Week 16 | 8.56 ± 1.284 | 7.09 ± 1.357 | 6.86 ± 1.359 | 8.30 ± 1.318 |
The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Mental Component Score | 4.63 ± 1.259 | 3.61 ± 1.350 | 5.31 ± 1.367 | 5.63 ± 1.286 |
| Physical Component Score | 3.66 ± 0.952 | 4.79 ± 1.019 | 2.66 ± 1.026 | 5.50 ± 0.972 |
The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Week 4 - Mental Component Score | 0.49 ± 1.091 | 1.89 ± 1.151 | 2.46 ± 1.149 | 2.18 ± 1.116 |
| Week 8 - Mental Component Score | 2.65 ± 2.267 | 3.80 ± 1.341 | 4.65 ± 1.363 | 3.35 ± 1.294 |
| Week 12 - Mental Component Score | 2.89 ± 1.188 | 5.42 ± 1.264 | 3.94 ± 1.265 | 4.59 ± 1.207 |
| Week 16 - Mental Component Score | 4.60 ± 1.214 | 3.00 ± 1.281 | 5.57 ± 1.291 | 5.46 ± 1.247 |
| Week 4 - Physical Component Score | 3.35 ± 0.844 | 3.94 ± 0.889 | 1.14 ± 0.878 | 1.98 ± 0.863 |
| Week 8 - Physical Component Score | 3.83 ± 0.894 | 4.56 ± 0.949 | 3.48 ± 0.941 | 3.47 ± 0.909 |
| Week 12 - Physical Component Score | 3.83 ± 0.894 | 4.56 ± 0.949 | 3.48 ± 0.941 | 3.47 ± 0.909 |
| Week 16 - Physical Component Score | 4.72 ± 0.968 | 4.67 ± 1.020 | 3.32 ± 1.021 | 4.57 ± 0.993 |
Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks | -23.64 ± 2.601 | -27.81 ± 2.751 | -28.13 ± 2.700 | -31.99 ± 2.630 |
Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Week 4 | -12.49 ± 2.327 | -10.50 ± 2.445 | -12.38 ± 2.361 | -18.67 ± 2.367 |
| Week 8 | -18.54 ± 2.239 | -16.53 ± 2.338 | -22.12 ± 2.374 | -24.85 ± 2.289 |
| Week 12 | -21.01 ± 2.299 | -20.72 ± 2.413 | -25.35 ± 2.341 | -27.25 ± 2.305 |
| Week 16 | -19.44 ± 2.572 | -24.49 ± 2.687 | -24.77 ± 2.676 | -25.77 ± 2.633 |
The PaGA of disease activity was performed using a 100 mm Visual Analog Scale (VAS) ranging from 0 (no disease activity) to 100 (maximal disease activity), in response to the question "Considering all the ways Sjögren's syndrome affects you, please draw a line on the scale to indicate how well you are doing today". A negative change from baseline is a favourable outcome.
| Scores on a scale | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Week 4 | -9.42 ± 2.850 | -10.02 ± 2.992 | -5.96 ± 2.969 | -8.96 ± 2.906 |
| Week 8 | -9.74 ± 3.035 | -11.48 ± 3.214 | -8.70 ± 3.271 | -15.27 ± 3.091 |
| Week 12 | -11.45 ± 3.064 | -17.51 ± 3.244 | -11.73 ± 3.234 | -13.57 ± 3.105 |
| Week 16 | -16.26 ± 3.194 | -17.56 ± 3.361 | -14.86 ± 3.375 | -15.78 ± 3.271 |
| Week 24 | -15.11 ± 3.405 | -12.83 ± 3.648 | -11.85 ± 3.704 | -19.87 ± 3.470 |
Change from baseline in salivary flow rate (unstimulated and stimulated) at 24 weeks as compared to placebo. Unstimulated saliva is a mix of serous and mucous secretions coming primarily from the submandibular and minor salivary glands. The parotid gland produces the largest volume of stimulated saliva. Stimulated saliva accounts for 80-90% of daily salivary production.
| mL/min | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) |
|---|---|---|---|---|
| Stimulated | 0.05 ± 0.067 | 0.16 ± 0.074 | 0.18 ± 0.071 | 0.25 ± 0.98 |
| Unstimulated | 0.00 ± 0.030 | 0.01 ± 0.034 | -0.00 ± 0.032 | -0.01 ± 0.031 |
B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.
| Percent change | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | Placebo - VAY150 mg | VAY736 300 mg - Placebo | VAY736 300 mg - VAY736 300 mg |
|---|---|---|---|---|---|
| Week 24 | -88.00 ± 5.784 | -99.07 ± 5.812 | 3.29 ± 5.674 | -103.0 ± 8.198 | -94.20 ± 8.098 |
| Week 28 | — | — | -97.06 ± 5.732 | -105.3 ± 9.145 | -91.80 ± 8.272 |
B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \>= 50 cells/μL) were analyzed by descriptive statistics. Baseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.
| months | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | Placebo - VAY150 mg | VAY736 300 mg - Placebo | VAY736 300 mg - VAY736 300 mg |
|---|---|---|---|---|---|
| Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts | 3.8 (2.7 to 5.2) | 4.8 (4.7 to 6.6) | 6.8 (5.0 to 9.2) | 8.4 (6.8 to 9.1) | 6.5 (4.9 to 7.5) |
Pharmacokinetic Concentrations This outcome only applies to patients who received at least one dose of VAY739 (so not applicable to placebo)
| ug/mL | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | VAY736 300 mg - Placebo | VAY736 300 mg - VAY736 300 mg |
|---|---|---|---|---|---|
| Peak Serum Concentration of VAY736 | 0.0747 ± 0.203 | 0.475 ± 0.380 | 1.46 ± 0.596 | 2.15 ± 1.47 | 1.94 ± 1.53 |
Collected over From first dose of study drug until end of follow-up period, up to approximately 3 years (max duration of follow-up was 2 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Up to Week 24) | 0/49 (0%) | 3/49 (6.1%) | 33/49 (67.3%) |
| VAY736 - 5 mg (Up to Week 24) | 0/47 (0%) | 0/47 (0%) | 40/47 (85.1%) |
| VAY736 - 50 mg (Up to Week 24) | 0/47 (0%) | 1/47 (2.1%) | 34/47 (72.3%) |
| VAY736 - 300 mg (Up to Week 24) | 0/47 (0%) | 2/47 (4.3%) | 41/47 (87.2%) |
| Any VAY736 (Up to Week 24) | 0/141 (0%) | 3/141 (2.1%) | 115/141 (81.6%) |
| ALL (Up to Week 24) | 0/190 (0%) | 6/190 (3.2%) | 148/190 (77.9%) |
| VAY736 - 5 mg 24 Weeks (Periods 2 and 4) | 0/47 (0%) | 3/47 (6.4%) | 41/47 (87.2%) |
| VAY736 - 50 mg 24 Weeks (Periods 2 and 4) | 0/47 (0%) | 7/47 (14.9%) | 37/47 (78.7%) |
| VAY736 - 150 mg 28 Weeks (Periods 3 and 4) | 0/47 (0%) | 9/47 (19.1%) | 41/47 (87.2%) |
| VAY736 - 300 mg 24 Weeks (Entire Study) | 0/26 (0%) | 5/26 (19.2%) | 24/26 (92.3%) |
| VAY736 - 300 mg 52 Weeks (Entire Study) | 0/21 (0%) | 5/21 (23.8%) | 20/21 (95.2%) |
| Any VAY736 - 300 mg (Periods 2, 3 and 4) | 0/47 (0%) | 10/47 (21.3%) | 44/47 (93.6%) |
| Any VAY736 (Periods 2, 3 and 4) | 0/188 (0%) | 29/188 (15.4%) | 163/188 (86.7%) |
| Event | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | Any VAY736 (Up to Week 24) | ALL (Up to Week 24) | VAY736 - 5 mg 24 Weeks (Periods 2 and 4) | VAY736 - 50 mg 24 Weeks (Periods 2 and 4) | VAY736 - 150 mg 28 Weeks (Periods 3 and 4) | VAY736 - 300 mg 24 Weeks (Entire Study) | VAY736 - 300 mg 52 Weeks (Entire Study) | Any VAY736 - 300 mg (Periods 2, 3 and 4) | Any VAY736 (Periods 2, 3 and 4) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/49 | 0/47 | 0/47 | 1/47 | 1/141 | 1/190 | 0/47 | 0/47 | 0/47 | 0/26 | 2/21 | 2/47 | 2/188 |
| PneumoniaInfections and infestations | 1/49 | 0/47 | 0/47 | 0/47 | 0/141 | 1/190 | 0/47 | 0/47 | 1/47 | 0/26 | 1/21 | 1/47 | 2/188 |
| Traumatic fractureInjury, poisoning and procedural complications | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 0/26 | 1/21 | 1/47 | 1/188 |
| MigraineNervous system disorders | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 0/26 | 1/21 | 1/47 | 1/188 |
| AnaemiaBlood and lymphatic system disorders | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 1/26 | 0/21 | 1/47 | 1/188 |
| Deafness neurosensoryEar and labyrinth disorders | 0/49 | 0/47 | 0/47 | 1/47 | 1/141 | 1/190 | 0/47 | 0/47 | 0/47 | 1/26 | 0/21 | 1/47 | 1/188 |
| COVID-19Infections and infestations | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 1/26 | 0/21 | 1/47 | 1/188 |
| COVID-19 pneumoniaInfections and infestations | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 1/26 | 0/21 | 1/47 | 1/188 |
| Weight decreasedInvestigations | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 1/26 | 0/21 | 1/47 | 1/188 |
| Device breakageProduct Issues | 0/49 | 0/47 | 0/47 | 0/47 | 0/141 | 0/190 | 0/47 | 0/47 | 0/47 | 1/26 | 0/21 | 1/47 | 1/188 |
| Event | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | Any VAY736 (Up to Week 24) | ALL (Up to Week 24) | VAY736 - 5 mg 24 Weeks (Periods 2 and 4) | VAY736 - 50 mg 24 Weeks (Periods 2 and 4) | VAY736 - 150 mg 28 Weeks (Periods 3 and 4) | VAY736 - 300 mg 24 Weeks (Entire Study) | VAY736 - 300 mg 52 Weeks (Entire Study) | Any VAY736 - 300 mg (Periods 2, 3 and 4) | Any VAY736 (Periods 2, 3 and 4) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 2/49 | 4/47 | 9/47 | 26/47 | 39/141 | 41/190 | 4/47 | 9/47 | 17/47 | 13/26 | 14/21 | 27/47 | 57/188 |
| Upper respiratory tract infectionInfections and infestations | 4/49 | 4/47 | 5/47 | 2/47 | 11/141 | 15/190 | 7/47 | 9/47 | 7/47 | 8/26 | 2/21 | 10/47 | 33/188 |
| NasopharyngitisInfections and infestations | 5/49 | 4/47 | 2/47 | 7/47 | 13/141 | 18/190 | 7/47 | 4/47 | 11/47 | 5/26 | 4/21 | 9/47 | 31/188 |
| Urinary tract infectionInfections and infestations | 4/49 | 6/47 | 2/47 | 0/47 | 8/141 | 12/190 | 9/47 | 5/47 | 7/47 | 2/26 | 3/21 | 5/47 | 26/188 |
| LeukopeniaBlood and lymphatic system disorders | 2/49 | 3/47 | 2/47 | 6/47 | 11/141 | 13/190 | 3/47 | 2/47 | 4/47 | 2/26 | 4/21 | 6/47 | 15/188 |
| DiarrhoeaGastrointestinal disorders | 4/49 | 3/47 | 2/47 | 3/47 | 8/141 | 12/190 | 3/47 | 3/47 | 2/47 | 3/26 | 4/21 | 7/47 | 15/188 |
| Back painMusculoskeletal and connective tissue disorders | 3/49 | 1/47 | 4/47 | 2/47 | 7/141 | 10/190 | 3/47 | 4/47 | 6/47 | 4/26 | 2/21 | 6/47 | 19/188 |
| HeadacheNervous system disorders | 7/49 | 4/47 | 4/47 | 4/47 | 12/141 | 19/190 | 5/47 | 5/47 | 4/47 | 4/26 | 2/21 | 6/47 | 20/188 |
| SinusitisInfections and infestations | 4/49 | 4/47 | 2/47 | 0/47 | 6/141 | 10/190 | 5/47 | 3/47 | 7/47 | 2/26 | 1/21 | 3/47 | 18/188 |
| Injection related reactionInjury, poisoning and procedural complications | 2/49 | 6/47 | 5/47 | 4/47 | 15/141 | 17/190 | 6/47 | 5/47 | 7/47 | 2/26 | 2/21 | 4/47 | 22/188 |
| Age, Continuous(Years) | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | Total |
|---|---|---|---|---|---|
| Mean | 47.9 ± 12.44 | 52.5 ± 13.64 | 51.0 ± 11.12 | 49.1 ± 15.41 | 50.9 ± 13.48 |
| Sex: Female, Male(Participants) | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | Total |
|---|---|---|---|---|---|
| Female | 47 | 46 | 41 | 46 | 180 |
| Male | 2 | 1 | 6 | 1 | 10 |
| Race/Ethnicity, Customized(Participants) | Placebo (Up to Week 24) | VAY736 - 5 mg (Up to Week 24) | VAY736 - 50 mg (Up to Week 24) | VAY736 - 300 mg (Up to Week 24) | Total |
|---|---|---|---|---|---|
| Asian | 4 | 3 | 10 | 5 | 22 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 44 | 42 | 37 | 42 | 165 |
| Unknown | 1 | 1 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2017 to primary completion in Jun 2020, 36 months.
Results were first posted in Oct 2024, 4 years 3 months after primary completion. A results delay was requested in Jul 2020.
Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab